Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030193 (pain)
 261,466 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A number of peripherally acting analgesics have become available in the past two decades for the treatment of mild to moderate pain of diverse etiology. The action of these agents is based on their putative ability to inhibit prostaglandin biosynthesis and attenuate hyperalgesia. Suprofen is a new and potent peripherally acting analgesic with anti-inflammatory and antipyretic properties which appears to inhibit prostaglandin synthetase in a tissue-selective manner. In preclinical studies, suprofen was shown to possess a wide separation of analgesic activity from gastrointestinal irritation. Suprofen appears to exert its pharmacological effect by inhibiting synthesis of prostaglandins from precursor arachidonic acid, inhibiting the pain induced by bradykinin, and by raising the threshold to pain induced by prostaglandins. The onset of action is rapid with peak analgesic effect reached in 1-2 h. Preclinical data suggest that suprofen may be an extremely valuable and versatile analgesic for the clinical management of pain.
 ...
PMID:Introduction to the pharmacology of suprofen. 636 87

The safety and efficacy of suprofen 200 mg q.i.d. and aspirin 650 mg q.i.d. in the treatment of chronic pain due to osteoarthritis were compared in a double-blind, randomized, parallel group study over a 12-week period. Suprofen was comparable to aspirin in the relief of pain and improvement in activity impairment. Results of ocular examination, laboratory data, and vital signs examinations indicated no clinically significant changes for suprofen. No serious side effects were reported by either group.
 ...
PMID:Long-term clinical evaluation of suprofen and aspirin in patients with osteoarthritis. 636 91

The effectiveness and safety of suprofen 200 mg, aspirin 650 mg, and placebo in the treatment of moderate to severe pain were compared in a 72-hour multiple-dose, double-blind, parallel, randomized study in 75 adults suffering from musculoskeletal pain. Suprofen was superior to aspirin and placebo for pain relief, total pain relief scores, pain severity, activity impairment, comparative evaluation of activity impairment, and comparative evaluation of pain and sleep, with differences achieving statistical significance for most parameters at the 24- to 72-hour evaluation points. 1 mild, transient side effect occurred in the suprofen group, 3 in the placebo group, and 4 of moderate intensity in the aspirin group. The effectiveness of multiple-dose treatment of musculoskeletal pain with suprofen 200 mg is superior to that of aspirin and placebo.
 ...
PMID:Multiple-dose comparison of suprofen, aspirin, and placebo in the treatment of musculoskeletal pain. 636 93

Suprofen 200 mg and suprofen 400 mg were found to be as efficacious as diflunisal 750 mg in a single-dose, double-blind randomized study of 130 hospitalized patients with pain following meniscectomy. Pain intensity was measured using both an interval scale and a visual analogue scale. Pain indices derived from both scales as well as the physician's global evaluation were consistent in demonstrating that suprofen is an effective analgesic agent in the relief of moderate to severe pain following orthopedic surgery.
 ...
PMID:Clinical comparison of the analgesic efficacy of suprofen, diflunisal and placebo in the treatment of pain after meniscectomy. 636 94

Suprofen is a potent, peripherally-acting, non-narcotic analgesic agent. The mechanism of action of the compound involves inhibition of prostaglandin biosynthesis and, perhaps, direct antagonism of the peripheral, pain inducing actions of prostaglandins, bradykinin and other pain mediators. Suprofen at a dose of 200 mg appears to be equal or greater in efficacy as an analgesic modality than those of ibuprofen, propoxyphene, naproxen and diflunisal or a combination of 650 mg aspirin plus 60 mg codeine. Its clinical utility has been amply demonstrated in the treatment of a number of types of pain including general and orthopedic surgery, episiotomy, post-partum pain, dysmenorrhea, dental pain and musculoskeletal disorders. Suprofen represents a new class of orally effective nonnarcotic analgesics with potential for effective clinical use in the treatment of pain.
 ...
PMID:Suprofen: the pharmacology and clinical efficacy of a new non-narcotic peripheral analgesic. 643 59

This 4-week, open design study was conducted to evaluate the efficacy and safety of suprofen (200-1,200 mg/day) in the treatment of elderly patients with pain of diverse origin, all of whom suffered from secondary disorders. All patients reported pain of moderate to very severe intensity upon study enrollment, which improved considerably in 89% of patients by week 1. 12 of the 16 patients reported good to very good pain reduction by week 4. Suprofen was extremely well tolerated by this patient population, and there were no drug-related study withdrawals. These results show suprofen to be a potentially useful drug for the treatment of elderly patients suffering from various painful conditions.
 ...
PMID:Clinical evaluation of suprofen in the treatment of elderly patients with pain of diverse etiology. 665 38

The antinociceptive properties of suprofen [alpha-methyl-4-(thienylcarbonyl)benzene acetic acid] are described in a pathologically induced hyperalgesic model, the rat adjuvant arthritis flexion test. By using this assay, suprofen was characterized as an orally effective, non-narcotic analgesic with a rapid onset and 4-hr duration of activity. Suprofen is 50 times more potent than acetaminophen, five times more potent than codeine and equipotent to the new peripheral analgesics, zomepirac and diflunisal. In combination experiments, suprofen potentiates the analgesic effects of acetaminophen and, unlike morphine, the analgesic effect of suprofen is not blocked by naloxone. In other hyperalgesic assays, suprofen is an extremely potent inhibitor of arachidonate-induced writhing and is equipotent to morphine in the yeast-induced paw edema (Randall-Selitto) assay. Additionally, suprofen is inactive on the normal paw in the Randall-Selitto test, the mouse Eddy hot-plate test and the tail withdrawal reflex assay induced by warm water in rats, all sensitive tests capable of detecting central (narcotic) but not peripheral analgesics. Activity on prostaglandin biosynthesis from several species and tissues suggests that suprofen is a tissue selective inhibitor of prostaglandin synthesis. These experiments suggest that suprofen represents a new class of potent, orally effective, peripheral (non-narcotic) analgesics with potential usefulness in a variety of clinical pain situations formerly reserved for narcotics.
 ...
PMID:Suprofen, a new peripheral analgesic. 699 57


<< Previous 1 2